Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?

Table 1 N-terminal fragment of the prohormone brain natriuretic peptide level and lipid metabolism parameters after 3-mo of omega-3 polyunsaturated fatty acid therapy

Parameter	Patients with T2DM and CAN (n = 36)
	Control (n = 15)	ω-3 PUFA (n = 21)
	Group 1	Group 2
NT-proBNP	-3.0 ± 1.1	-6.8 ± 1.1a
LDL cholesterol	-8.3 ± 1.4	-12.8 ± 1.9
HDL cholesterol	4.1 ± 1.0	7.1 ± 0.5a
ТG	-8.3 ± 1.2	-35.4 ± 2.6c
TC	-6.7 ± 1.0	-8.2 ± 1.1

The results are presented as % change from baseline, (Δ%, Mean ± SEM);

^aP < 0.05,

^cP < 0.001. T2DM: Type 2 diabetes mellitus; CAN: Cardiac autonomic neuropathy; ω-3 PUFA: Omega-3 polyunsaturated fatty acid; NT-proBNP: N-terminal fragment of the prohormone brain natriuretic peptide; LDL cholesterol: Low density lipoprotein cholesterol; HDL cholesterol: High density lipoprotein cholesterol; ТG: Triglycerides; TC: Total cholesterol.